



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 8

Complete if Known

Application Number	10/594,420
Filing Date	May 18, 2005
First Named Inventor	SUN
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	17357.01701US

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 4,560,774	12-24-1985	Pettit et al.	
		US- 4,833,257	05-23-1989	Pettit et al.	
		US- 5,072,004	12-10-1991	Pettit	
		US- 5,196,447	03-23-1993	Pettit et al.	
		US- 5,288,514	02-22-1994	Ellman	
		US- 5,359,115	10-25-1994	Campbell et al.	
		US- 5,362,899	11-08-1994	Campbell	
		US- 5,393,897	02-28-1995	Pettit et al.	
		US- 5,625,232	04-29-1997	Numata et al.	
		US- 5,891,870	04-06-1999	Driedger et al.	
		US- 5,891,906	04-06-1999	Driedger et al.	
		US- 5,955,501	09-21-1999	Driedger et al.	
		US- 5,962,498	10-05-1999	Driedger et al.	
		US- 5,962,504	10-05-1999	Kozikowski et al.	
		US- 6,043,270	03-28-2000	Driedger et al.	
		US- 6,080,784	06-27-2000	Driedger et al.	
		US- 6,187,568 B1	02-13-2001	Nishida et al.	
		US- 2003/017385 A1	09-11-2003	Alkon et al.	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁴
		Country Code ² Number *Kind Code ³ (if known)				
		WO 91/07087	05-30-1991	Affymax Technologies, N.V.		
		WO 92/10092	06-25-1992	Affymax Technologies, N.V.		
		WO 93/20242	10-14-1993	The Scripps Research Inst.		
		WO 93/09668	05-27-1993	Affymax Technologies, N.V.-		
		WO 94/08051	04-14-1994	The Trustees of Columbia Univ.		
		WO 02/097423 A3	11-07-2002	BRNI		

Examiner Signature	/Sahar Javanmard/	Date Considered	08/04/2011
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/594,420
		Filing Date	May 18, 2005
		First Named Inventor	SUN
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Attorney Docket Number	17357.01701US		
Sheet	3	of	8

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Sun et al., "Carbonic anhydrase gating of attention: memory therapy and enhancement," TRENDS in Pharmacological Sciences, Vol. 23, No. 2, February 2002	
		Sun et al., "Functional switching of GABAergic synapses by ryanodine receptor activation," Proc. Nat'l. Acad. Sci USA, 97: 12300-12305, 2000	
		Battaini, "Protein Kinase C Isoforms as Therapeutic Targets in Nervous System Disease States," Pharmacological Research, Vol. 44, No. 5, 2001	
		Coull et al., "Altered brain protein kinase C in depression: a post-mortem study," European Neuropsychopharmacology 10 (2000) 283-288	
		Manji et al., "Post-receptor Signaling Pathways in the Pathophysiology and Treatment of Mood Disorders," Mood Disorders, pp 481-489	
		Bouron et al., "Acute Application of the Tricyclic Antidepressant Desipramine Presynaptically Stimulates the Exocytosis of Glutamate in the Hippocampus, Neuroscience, Vol. 90, No. 3, pp. 729-736, 1999	
		Budziszewska et al., "Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism," British Journal of Pharmacology, (2000) 130, 1385-1393	
		Morishita et al., "Effects of tricyclic antidepressants on protein kinase C activity in rabbit and human platelets in vivo," Journal of Affective Disorders 70 (2002) 329-332	
		Casini et al., "Carbonic Anhydrase Activators. The Selective Serotonin Reuptake Inhibitors Fluoxetine, Sertraline and Citalopram Are Strong Activators of Isozymes I and II," Bioorganic & Medicinal Chemistry Letters 13 (2003) 2765-2768	
		Wang et al., "Fluoxetine Depresses Glutamate Exocytosis in the Rat Cerebrocortical Nerve Terminals (Synaptosomes) via Inhibition of P/Q Ca2+ Channels," SYNAPSE 48:170-177 (2003)	

Examiner Signature	/Sahar Javanmard/	Date Considered	08/04/2011
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by this public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/594,420
		Filing Date	May 18, 2005
		First Named Inventor	SUN
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	17357.01701US
Sheet	4	of	8

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Gould et al., "Signaling networks in the pathophysiology and treatment of mood disorders," Journal of Psychosomatic Research 53 (2002) 687-697	
		Abramets et al., "Behavioral Depression-Related Modifications of the Properties of Glutamatergic Synapses in the Basolateral Amygdalar Nucleus in Rats," Neurophysiology, Vol. 34, No. 4, 2002	
		Shelton, "Cellular Mechanisms in the Vulnerability to Depression and Response to Antidepressants," DEPRESSION, Vol. 23, No. 4, December 2000	
		Popoli et al., "Second Messenger-Regulated Protein Kinases in the Brain: Their Functional Role and the Action of Antidepressant Drugs," J. Neurochem., Vol. 74, No. 1, 2000	
		Johnston-Wilson et al., "Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder," Molecular Psychiatry (2000) 5, 142-149	
		Morishita et al., "Different effect of desipramine on protein kinase C in platelets between bipolar and major depressive disorders," Psychiatry and Clinical Neurosciences (1999), 53, 11-15	
		Lieb et al., "Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P receptor," Journal of Neurochemistry, 2003, 86, 69-76	
		Suzuki et al., "Altered 5-HT-Induced Calcium Response in the Presence of Staurosporine in Blood Platelets from Bipolar Disorder Patients," Neuropsychopharmacology (2003) 28, 1210-1214	
		Hayes, "Acetazolamide in Bipolar Affective Disorders," Annals of Clinical Psychiatry, Vol. 6, No. 2, 1994	
		Lenox et al., "Lithium and the Brain: A Psychopharmacological Strategy to a Molecular Basis for Manic Depressive Illness," Clin. Chem. 40/2, 309-314 (1994)	

Examiner Signature	/Sahar Javanmard/	Date Considered	08/04/2011
---------------------------	-------------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

5

of

8

Complete if Known

Application Number	10/594,420
Filing Date	May 18, 2005
First Named Inventor	SUN
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	17357.01701US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Wang et al., "Increased membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients," Journal of Psychiatric Research 33 (1999) 171-179	
		Manji et al., "Protein Kinase C Signaling in the Brain: Molecular Transduction of Mood Stabilization in the Treatment of Manic-Depressive Illness," Biol Psychiatry 1999; 46:1328-1351	
		Pandey et al., "Protein Kinase C and Phospholipase C Activity and Expression of Their Specific Isozymes is Decreased and Expression of MARCKS is Increased in Platelets of Bipolar but Not in Unipolar Patients," Neuropsychopharmacology, 2002, Vol. 26, No. 2	
		Yildiz, "Phosphoinositide metabolism, lithium and manic depressive illness," Spectroscopy 16 (2002) 307-316	
		Barbas et al., "Multiple Serotonergic Mechanisms Contributing to Sensitization in Aplysia: Evidence of Diverse Serotonin Receptor Subtypes," Serotonin & Memory, pp. 373-386	
		Pandey et al., "Protein Kinase C in Platelets of Depressed Patients," Biol Psychiatry 1998; 44:909-911	
		Besag, "Behavioral Effects of the New Anticonvulsants," Drug Safety 2001: 24(7) 513-536	
		Hahn et al., "Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder," Bipolar Disorders 1999; 2: 81-86	
		International Search Report for PCT/US2005/017158 dated December 14, 2006	
		Mannisto, P.T. et al., "Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression", European Journal of Pharmacology 274 (1995) 229-233	

Examiner Signature	/Sahar Javanmard/	Date Considered	08/04/2011
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/594,420
		Filing Date	May 18, 2005
		First Named Inventor	SUN
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet 6	of 8	Attorney Docket Number	17357.01701US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kravitz, H.M. et al., "Dietary supplements of phenylalanine and other amino acid precursors of brain neuroamines in the treatment of depressive disorders", Journal of the American Osteopathic Associate 1984 United states, Vol. 84, No. 1 Suppl., 1984, pp. 119-123, XP008067181	
		Chetkovich, D.M., et al., "N-Methyl-D-aspartate receptor activation increases cAMP levels and voltage-gated Ca ²⁺ channel activity in area CA1 of hippocampus", Proc. Natl. Acad. Sci. USA Vol. 88, pp. 6467-6471, August 1991	
		C-T Hu, Mickey, et al., "Human fibroblast growth factor-18 stimulates fibroblast cell proliferation and is mapped to chromosome 14p11", Oncogene (1999) 18, 2635-2642	
		C-T Hu, Mickey, et al., "FGF-18, a Novel Member of the Fibroblast Growth Factor Family, Stimulates Hepatic and Intestinal Proliferation", Molecular and Cellular Biology, Oct. 1998, p. 6063-6074	
		Mody, Monica, et al., "Genome-wide gene expression profiles of the developing mouse hippocampus", PNAS, July 27, 2001, Vol. 98, No. 14, p. 8862-8867	
		Cavallaro, Sebastiano, et al., "Late memory-related genes in the hippocampus revealed by RNA fingerprinting", Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 9669-9673, September 1997	
		Tsien, Joe Z., et al., "The Essential Role of Hippocampal CA1 NMDA Receptor-Dependent Synaptic Plasticity in Spatial Memory", Cell, Vol. 87, 1327-1338, December 27, 1996	
		Ohbayashi, Norihiko, et al., "Structure and Expression of the mRNA Encoding a Novel Fibroblast Growth Factor, FGF-18", The Journal of Biological Chemistry, Vol. 273, No. 29, Issue of July 17, pp. 18161-18164, 1998	
		Calo, Girolamo, et al., "Pharmacology of nociceptin and its receptor: a novel therapeutic target", British Journal of Pharmacology (2000) 129, 1261-1283	
		Gomez, Marie, et al., "Ca ²⁺ Signaling via the Neuronal Calcium Sensor-1 Regulates Associative Learning and Memory in C. elegans", Neuron, Vol. 30, 241-248, April 2001	

Examiner Signature	/Sahar Javanmard/	Date Considered	08/04/2011
---------------------------	-------------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 7 of 8

Complete if Known

Application Number	10/594,420
Filing Date	May 18, 2005
First Named Inventor	SUN
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	17357.01701US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Masson, J., et al., "Neurotransmitter Transporters in the Central Nervous System", Pharmacological Reviews, Vol. 51, No. 3	
		Katzoff, Ayelet, et al., "Nitric Oxide Is Necessary for Multiple Memory Processes after Learning That a Food Is Inedible in Aplysia", The Journal of Neurosciences, November 1, 2002, 22(21): 9581-9594	
		Kornhauser, Jon M., et al., "A Kinase to Remember: Dual Roles for MAP Kinase in Long-Term Memory", Neuron Vol. 18, 839-842, June, 1997	
		Impey, Soren, et al., "Making New Connections: Role of ERK/MAP Kinase Signaling in Neuronal Plasticity", Neuron, Vol. 23, 11-14, May, 1999	
		Zhen, Xuechu, et al., "The p38 Mitogen-Activated Protein Kinase Is Involved in Associative Learning in Rabbits", The Journal of Neuroscience, August 1, 2001, 21(15):5513-5519	
		Davis, Roger J., "The Mitogen-activated Protein Kinase Signal Transduction Pathway", The Journal of Biological Chemistry, Vol. 268, No. 20, Issue of July 15 pp. 14553-14556, 1993	
		Berman, Diego E., et al., "Specific and Differential Activation of Mitogen-Activated Protein Kinase Cascades by Unfamiliar Taste in the Insular Cortex of the Behaving Rat", The Journal of Neuroscience, December 1, 1998, 18(23):1003-10044	
		Zhang, Wandong, et al., "Citron Binds to PSD-95 at Glutamatergic Synapses on Inhibitory Neurons in the Hippocampus", The Journal of Neuroscience, January 1, 1999, 19 (1):96-108	
		Kosik, Kenneth S., et al., "Microtubule-associated protein 2: Monoclonal antibodies demonstrate the selective incorporation of certain epitopes into Alzheimer neurofibrillary tangles", Proc. Natl. Acad. Sci. USA, Vol. 18, pp. 7941-7945, December 1984	
		Yamanouchi, Hideo, et al., "Early forms of microtubule-associated protein are strongly expressed in cortical dysplasia", Acta Neuropathol (1998) 95:466-470	

Examiner Signature	/Sahar Javanmard/	Date Considered	08/04/2011
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **8** of **8****Complete if Known**

Application Number	10/594,420
Filing Date	May 18, 2005
First Named Inventor	SUN
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	17357.01701US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Woolf, Nancy J., et al., "Hippocampal microtubule-associated protein-2 alterations with contextual memory", Brain Research, March 6, 1999, 821(1):241-249	
		Berke, Joshua, et al., "Dopamine and Glutamate Induce Distinct Striatal Splice Forms of Ania-6, an RNA Polymerase II-Associated Cyclin", Neuron, Vol. 32, 277-287, October 25, 2001	
		Tischmeyer, W., et al., "Activation of immediate early genes and memory formation", CMLS, Cell. Mol. Life Sci. 55 (1999) 564-574	

Examiner Signature	/Sahar Javanmard/	Date Considered	08/04/2011
---------------------------	-------------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./